These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
7. Stalevo reduction in dyskinesia evaluation in Parkinson's disease results were expected from a pharmacokinetic viewpoint. Nyholm D; Askmark H; Aquilonius SM Ann Neurol; 2011 Feb; 69(2):424; author reply 425. PubMed ID: 21387388 [No Abstract] [Full Text] [Related]
8. Bullous skin eruption associated with entacapone. Foti C; Cassano N; De Mari M; Sorino M; Vena GA Int J Dermatol; 2004 Jun; 43(6):471-2. PubMed ID: 15186236 [No Abstract] [Full Text] [Related]
9. [Neuromuscular disorders due to adverse effects of antiparkinson agents]. Hattori N Nihon Naika Gakkai Zasshi; 2007 Aug; 96(8):1614-20. PubMed ID: 17802710 [No Abstract] [Full Text] [Related]
10. Continuous dopaminergic therapy in Parkinson disease: time to stride back? Stoessl AJ Ann Neurol; 2010 Jul; 68(1):3-5. PubMed ID: 20583222 [No Abstract] [Full Text] [Related]
12. Severe hypertension following ephedrine administration in a patient receiving entacapone. Renfrew C; Dickson R; Schwab C Anesthesiology; 2000 Dec; 93(6):1562. PubMed ID: 11149468 [No Abstract] [Full Text] [Related]
13. Immediate versus delayed switch from levodopa/carbidopa to levodopa/carbidopa/entacapone: effects on motor function and quality of life in patients with Parkinson's disease with end-of-dose wearing off. Lew MF; Somogyi M; McCague K; Welsh M; Int J Neurosci; 2011 Nov; 121(11):605-13. PubMed ID: 21843110 [TBL] [Abstract][Full Text] [Related]
14. Is there a difference between levodopa/ dopa-decarboxylase inhibitor and entacapone and levodopa/dopa-decarboxylase inhibitor dose fractionation strategies in Parkinson's disease patients experiencing symptom re-emergence due to wearing-off? The Honeymoon Study. Destée A; Rérat K; Bourdeix I Eur Neurol; 2009; 61(2):69-75. PubMed ID: 19039224 [TBL] [Abstract][Full Text] [Related]
16. Enterocolic lymphocytic phlebitis and lymphocytic colitis: drug-related coexistent pathology. Jain R; Chetty R Int J Colorectal Dis; 2009 Apr; 24(4):473-4. PubMed ID: 18758788 [No Abstract] [Full Text] [Related]
17. Problems with the present inhibitors and a relevance of new and improved COMT inhibitors in Parkinson's disease. Kaakkola S Int Rev Neurobiol; 2010; 95():207-25. PubMed ID: 21095464 [TBL] [Abstract][Full Text] [Related]
18. Adherence with levodopa/carbidopa/entacapone versus levodopa/carbidopa and entacapone as separate tablets in patients with Parkinson's disease. Delea TE; Thomas SK; Hagiwara M; Mancione L Curr Med Res Opin; 2010 Jul; 26(7):1543-52. PubMed ID: 20429819 [TBL] [Abstract][Full Text] [Related]